# Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Study · id `cardio:ct-nct01384747` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01384747](<https://clinicaltrials.gov/study/NCT01384747>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01384747

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

## Technical summary

Registry record NCT01384747. Randomized; triple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2018-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT01384747, source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)
- Start date: 2011-07 (registry gives no type) (ClinicalTrials.gov record NCT01384747, source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)
- Primary completion: 2018-03 (actual) (ClinicalTrials.gov record NCT01384747, source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)
- Completion: 2018-03 (actual) (ClinicalTrials.gov record NCT01384747, source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01384747, source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01384747-2018-06-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
- Condition: Coronary Artery Disease
- Intervention (Drug): Fimasartan
- Intervention (Drug): Placebo
- Lead sponsor: Seung-Jung Park
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER
- Collaborator: Boryung Pharmaceutical Co., Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Seung-Jung Park (`cardio:org-seung-jung-park`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)
- Registry lists this organization as a collaborator: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 6cf2f7d57820b0baee5f9934173b35aab173cf49051eeabb0dd07deba9e8fb50
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
